Lyme disease, science, and society: Camp Other
Showing posts with label 2011. Show all posts
Showing posts with label 2011. Show all posts

Thursday, May 31, 2012

2 Anonymous Comments On Chronic Lyme Disease

Last year someone who identified only as "anonx" wrote some interesting comments on last January's blog post on quorum sensing, "How bacteria "talk" and how to make them shut up". (There is a fascinating video there by researcher Bonnie Bassler. I highly recommend checking it out.)

To my knowledge, comments on Blogger do not get syndicated on post rss feeds - though one can request rss comments separately. I think that anonx's comments are worth taking another look, so I have decided to repost select excerpts of them here. (Refer back to the original comment thread for the CO side of the dialog, if needed.)

Anonymous January 21, 2011 5:06:00 PM HST
persister cells
quorum sensing
round bodies
blebs
biofilms made of borrelia
biofilms made of a mix of pathogens
symbiosis in all its forms and iterations
intracellularity
the cascade of genospecies and strains
quiescence and dormancy
transfections
borrelia stuck in B cells with CLIP attached
the role of toll-like receptors&inflammation
the growing list of possible co-infections
xmrv
new view of PANDAS that goes way beyond strep...
molecular mimicry

guess I'll stop here but I could go on --you just need a little proof: not just proof it is happening but proof that treating it will end the illness. that's the problem.

Anonymous January 21, 2011 11:03:00 PM HST

Don't you think that looking at persistence in isolation could be futile, given the large number of people treated for years without cure? Persistence could be the imperceptible spark that incites an immune tsunami. What if it is easier to treat the tsunami --by its nature outsized and blatant and in your face-- than the spark which, though present and incendiary, we cannot find? Is it possible that the yin and yang nature of the fight has prevented a view of the system overall? What if a tiny amount of infection has caused a huge inflammatory response? What if that infection is hiding in B cells because a glitch in the system has prevented T cells from recognizing the foreign invader, and thus, from finishing the job? What IF to get rid of the persistent infection, you must treat immune dysfunction first? So no ...I don't think it is as simple as you say, or that by conceiving the issue along the old paradigms of the fight, raging fruitlessly for 30 years, you will get what you want ... unless of course, it is really as simple as you suggest. I mean, what if you prove persistence, but it still won't bring a cure?

Anonymous January 22, 2011 11:57:00 AM HST

regarding the four trials cited, they do in fact show benefit to retreatment for fatigue and pain --and thus, in fact do not match with the wording of the conclusions rendered or (in the case of two of three authors) forced down those authors throats by the powers that be. There is actually ample evidence in these trials to suggest a benefit to retreatment and longer treatment --and in the case of the Klempner trial, serious issues with methodology. But as you say, the outcome of these trials must be detached from pathophysiology --what is the mechanism of the benefit? That question the trials do not address.

Still, to detach infection from immune response is just plain wrong-headed. We are 10% by weight bacteria, and most of those organisms are beneficial. The question is --which are the pathogens, and how do those pathogens do us in? In every case, inflammation and cellular immunity are going to play a role.

Anonymous January 22, 2011 11:15:00 PM HST

It is a very complicated problem, as you say.

It is TRUE that if you suppress inflammation infection would spiral out of control: The murine studies on borrelia and toll-like receptors show that to be right.

But here's the thing: Most researchers, even most of the IDSA researchers, don't actually deny that organisms can persist. They just deny that those quiescent remaining organisms are driving the continued symptoms --they say these persisting borrelia are too few, and too dormant. And they would cite the research on quorum sensing to support their case.

As I see it, it is not really persistence you need to prove, but rather, the mechanism by which persistence at the low level research suggests drives the disease. Inflammation is not the only immune mechanism --cellular immunity or dysfunction thereof can play havoc, too, and persistent infection could drive it in an endless loop.

Also: Treatment studies without knowing more about pathophysiology can work against you, because --hell-- they are just empiricism on top of empiricism, more wandering in the dark.

I contend you need more basic biology to target such studies, strategically. If you were to move forward without that, you would need an elaborate methodology with many variables and large enough numbers of patients to test for many possibilities and separate the data from the noise. And with Lyme patients still so ill-defined, with no test extant for active infection ...

Makes my head spin. A hundred million dollars would help.

Anonymous January 23, 2011 1:34:00 PM HST

Other,

My comments refer specifically to the Barthold work, with which I am extremely familiar. Barthold's findings of small numbers of dormant, quiescent spirochetes within collagen across the range of mammalian species following treatment have been well-known inside the mainstream (though published only recently) for decades. There is no great rush to debunk Barthold, whose research really is beyond dispute --Barthold himself being an especially meticulous and careful scientist. What his critics say, however, is that these spirochetes are not active enough and not numerous enough to cause disease. (to wit: issue of quorum sensing.) Barthold theorizes otherwise, contending that the small numbers of chetes may provoke an outsized --but heretofore undetected-- cytokine cascade that causes the disease. Barthold would classify this cascade under the heading of INFLAMMATORY response. This is his theory --and a powerful one that should be explored.

You may have noticed that NIH has begun to test the Barthold work with a study of xenodiagnosis, but patients are protesting that study for fear that the ticks used might not be as naive as claimed: And really, given the confusion over pathogens involved, who knows?

Other theories of persistence to pursue include the impact of round bodies AND the work of Newell, who finds Borrelia stuck inside B cells because of a dysfunction in MHC.

In the case of Newell, especially, the notion is that persistent infection can never be cured without correcting the recognition dysfunction of MHC. In other words, even though the disease is driven by persistence, Newell says you have to correct the immune problem first.

And by the way, both she and Barthold insist you can never entirely clear borrelia infection with antibiotics alone --you need the immune system to do the final kill, and so you must have an immune correct FIRST, even if the driver is persistence.

Or it could be the round bodies... but whatever it is, it is complicated --and simply fueling the fight of persistence versus immunity isn't helpful.

There is a difference between what patients use to get well right now --the ax in the form of huge quantities of endless suppressive antibiotics-- and what they should want for the future --the chisel, which could well be an immune correction that allows infection finally to be resolved. There should be a divide between the effort to protect a Lyme doc in the here and now and the direction of research for the future --but it is hard for a lot of people to understand this.

I agree with you that if we knew the mechanism we would have a target --and that is why I am so equivocal if not outright squeamish about the continued treatment trials some patients are calling for.

What are they treating? --and if they don't really know, there is a big risk that study could bury them deeper and darker than ever before.

anonx

Anonymous  January 23, 2011 7:27:00 PM HST

Given current state of knowledge immune treatments could backfire, big time --as the literature shows. If you look at the work on toll-like receptors you find a genetic curve for inflammatory response to borrelia ranging from almost nothing to off-the-charts and everything in between. That is just one immune parameter, and there are many others. These parameters could vary for every infection or strain and every person. Therefore it is possible with current state of knowledge that suppressive abx are really the best we have... there needs to be a crunching of data to understand what we are looking at --otherwise, it is just stumbling in the dark. The amazing thing is that the IDSA crew has gotten away with such a grotesquely oversimplified story of this disease for so long --and that to explain it, they perpetuate the explanation that it is a psychosis instead of a complex spectrum of infection and immune response. But by giving an oversimplified rejoinder, patients have hurt their cause, too.

In a gross way one could do a study treating infection, treating immune issues or treating both: but this would be very crude without more data up front.

anonx


Comments:

So I do have a few comments on this, now that it's nearly a year and half since these comments were posted. My thoughts on the matter have shifted over time, and after exposure to more research.


  • I'd like to see evidence that Borrelia burgdorferi is hiding in B cells in vivo. That would be informative. There has been some mention of Bb being intracellular in a few in vitro studies and one in  vivo study; we need more.
  • This anonymous author may be on to something, and it may be that the host immune response may need to be addressed in order to manage the remaining infection if it is still present. Not enough is known, but when I read about filgrastim and rixtuximab and how they have some positive effect on a patients with persisting symptoms of Lyme disease or CFS/ME,  I think that adjusting the host immune response is an avenue worth exploring. It should have been explored more years ago.
  • I still think the trials must be detached from pathophysiology. My position on this has not changed. Treatment trials have done nothing to provide evidence of persistence of Borrelia burgdorferi one way or the other.
  • I strongly agree we need more basic biology research. The anonymous author's comments on the role the immune system plays in infection are noteworthy. But we also need to know what is going on if the infection does persist in some form. Is there a persister phenotype? Ongoing research into persister phenotypes should not be neglected. But I wouldn't leave all research at that, because there are other hypotheses to consider.
  • One thing I wonder about is the issue of quorum sensing and efficiency sensing, and if blebs or vesicles play any role in the dissemination and pathogenesis of Borrelia burgdorferi. Blebs as a form of communication are observed in other bacterial species, and perhaps Bb uses blebs and vesicles in a different manner and they are not part of cells undergoing apoptosis. Plasmid DNA and outer surface lipoproteins have been found within blebs; there is some suggestion of blebs containing adhesins... I think there's more to blebs than meets the eye.
  • Anonymous said, "There is a difference between what patients use to get well right now --the ax in the form of huge quantities of endless suppressive antibiotics-- and what they should want for the future --the chisel, which could well be an immune correction that allows infection finally to be resolved. There should be a divide between the effort to protect a Lyme doc in the here and now and the direction of research for the future --but it is hard for a lot of people to understand this." I keep reflecting on what they wrote, and its implications. Is there a more targeted approach which could be designed to help treat patients?" I think they are right - there is no reason why patients cannot ask for protection for the treatment they are receiving now while promoting research on new and different treatments. I think VGV-L is one effort in this direction, but I am not sure it will work. There is a lot of complexity involved.
  • Last but not least, my anonymous commenter said this: "The amazing thing is that the IDSA crew has gotten away with such a grotesquely oversimplified story of this disease for so long --and that to explain it, they perpetuate the explanation that it is a psychosis instead of a complex spectrum of infection and immune response. But by giving an oversimplified rejoinder, patients have hurt their cause, too." 

I think there's a lot of truth in that last statement. Now, what does one do about it?


Read More

Wednesday, March 14, 2012

10 2011 Guidelines For Treating Lyme Disease...

... from Russia are here. With love.

This past weekend I got into a lengthy discussion with "radicale" on the Embers et al Issues a Statement post, and somewhere along the line, amid over 50 comments there (I highly recommend reading them, too), radicale advised that I check out documentation and research on Lyme disease from Russia and the Balkans.

So I did, and I did in part because he's the one who told me that treatment for both acute and disseminated Lyme disease in Serbia - particularly at two hospitals in the country - is more aggressive by default than it is either in the US or in Canada. He also stated that this treatment is backed by clinical studies (two of which are mentioned in the comments on the above post) - and because it was his home country and had this scientific backing, he went there for treatment for Lyme disease rather than in Canada.

He shared what he said was the standard antibiotic treatment schedule for Lyme disease given to patients in a few hospitals in Serbia:

"It is interesting that in Serbia, where every third tick is infected, amoxicillin is the drug of choice and it is routinely given for 6 weeks for early Lyme Disease.

In addition, disseminated Lyme Disease is treated in the following manner:

1) 4 weeks of ceftriaxone 2g/day plus metronidazole 500 mg bid
or three weeks of amoxicillin 1g tid followed by three weeks doxycycline 200mg bid plus metronidazole 500 mg bid
2) in case of persisting symptoms therapy is extended using pulsed doses up to 6 months

There are open-label control studies to support this type of treatment (in Serbian)."

I found this difference in approach to treatment interesting and I wanted a confirmation with a reliable source - so I have requested more information from him in terms of a citation for official guidelines using this antibiotic treatment.

While awaiting his response, I decided to see if I could find guidelines for other countries in the region and translate them. So far, I have found the 2011 guidelines for treatment of tickborne Borreliosis (they call it SDS) for Russia and ran them through Google Translate.

They are - as you will see - pretty bare bones relative to the guidelines document written up by either the IDSA or ILADS... And oh, OPTIONS... We have OPTIONS... did I say we have options? Yes, only I don't know what all the options actually are yet - I would have to figure out what all the drugs are by name.

Far as I can tell, Azitroks = azithromycin. doksitsi-wedge is, I think, some form of liquid doxycycline that is highly absorbent. klaforan = Claforan. Instructions at the bottom "per os" means "by mouth" or "orally".

I can figure out what some of the other drugs are due to their spelling coming close to the English word - but other drugs are unknown to me by the name being used...

APPROVED
Head of the Department of Health
Tomsk Oblast
O.S. Kobyakov
2011
Lepekhin A.
MD, Professor, Head of
Infectious Diseases and Epidemiology, State Educational Institution SSMU Health Ministry of Russia

Lukashova L.
MD, Professor, Department of Infectious Diseases and Epidemiology
GOU VPO SSMU Health Ministry of Russia

Ilyinskikh EN
MD, Professor, Department of Infectious Diseases and Epidemiology
GOU VPO SSMU Health Ministry of Russia

Zhukov, N.
MD, Professor of Neurology and Neurosurgery
GOU VPO SSMU Health Ministry of Russia

Portnyagina EV
PhD, Assistant Professor of Epidemiology and Infectious Diseases
GOU VPO SSMU Health Ministry of Russia

Dobkin, MN
PhD, chief freelance specialist in infectious
Health Department of the Tomsk region

Guidelines for Physicians
(Third edition, revised and enlarged)

Tomsk - 2011

THERAPY PROGRAM SDS

Schemes of causal treatment for tickborne Lyme Borreliosis

During the acute, manifest form (mild)

(Schema therapy - individual choice of doctor)
A. Amoxicillin 0.5 g three times daily per os (0.375 g of amoxiclav three times daily
per os), 14 days.
 or
Two. Azitroks 0.5 1 g once a day per os, 6 days.
 or
Three. Doxycycline 0.1 g 2 times a day per os, 14 days.

During the acute, manifest form (medium severity)

(Schema therapy - individual choice of doctor)
A. Ceftriaxone 1.0 g 2 times a day by intravenous drip, and 7 days, then - Amoxil-
penicillin of 0.75 g 3 times daily per os (0.375 g of amoxiclav three times daily per os),
7 days.
  or
Two. Ceftriaxone 1.0 g 2 times a day by intravenous drip, and 7 days, then - doksitsi-
wedge of 0.2 g 2 times a day intravenous drip, and 7 days.
 or
Three. 0.75 g of amoxicillin three times daily per os (0.560 g of amoxiclav three times daily
per os), 7 days, then - Azitroks 0.5 g of 1 time per day per os, 6 days.
 or
4. Doxycycline 0.2 g 2 times a day intravenous drip, and 7 days, then - Azitroks
0.5 1 g once a day per os, 6 days.

During the acute, manifest form (severe severity)

(Schema therapy - individual choice of doctor)
A. Ceftriaxone 2.0 g 2 times a day intravenous drip, and 10 days later - Amoxil-
penicillin at 1.0 g three times daily per os (amoxiclav, 0.625 g 3 times daily per os),
10 days.
 or
Two. Ceftriaxone 2.0 g 2 times a day intravenous drip, and 10 days later - doksitsi-
wedge of 0.2 g 2 times a day intravenous drip, and 10 days.
 or
Three. Amoxicillin 1.0 g three times daily per os (amoxiclav, 0.625 g 3 times a day
per os), 7 days, then - Azitroks of 1.0 g of 1 time per day per os in a 1-day and 0.5 g of 1
once a day per os for the next 5 days.
 or
4. Doxycycline 0.2 g 2 times a day intravenous drip, and 7 days, then - Azitroks 1.0 g of 1 time per day per os in 1-day and 0.5 g of 1 time per day per os for at- the next 5 days.

8Podostroe for (mild)

(Schema therapy - individual choice of doctor)
A. Ceftriaxone 1.0 g of a once-daily intravenous infusion, and 10 days later - doksitsi-
wedge of 0.1 g 2 times a day intravenous drip, and 10 days.
 or
Two. Amoxicillin 0.5 g three times daily per os (amoxiclav, 0.625 g 3 times a day
per os), 10 days later - doxycycline 0.1 g 2 times daily intravenous-drip
10 days.

Subacute (medium severity)

(Schema therapy - individual choice of doctor)
A. Ceftriaxone 1.0 g of a once-daily intravenous infusion, and 10 days later - doksitsi-
wedge of 0.2 g 2 times a day intravenous drip, and 10 days.
 or
Two. Ceftriaxone 1.0 g of a once-daily intravenous infusion, and 10 days later - Amoxil-
penicillin of 0.75 g 3 times daily per os (0.375 g of amoxiclav three times daily per os),
10 days.

Subacute (severe severity)

(Schema therapy - individual choice of doctor)
A. Ceftriaxone 2.0 g of a once-daily intravenous infusion, and 10 days later - doksitsi-
wedge of 0.2 g 2 times a day intravenous drip, and 10 days.
 or
Two. Ceftriaxone 2.0 g of a once-daily intravenous infusion, and 10 days later - Amoxil-
penicillin at 1.0 g three times daily per os (amoxiclav, 0.625 g 3 times daily per os),
10 days.

Chronic (phase compensation)

(Schema therapy - individual choice of doctor)
A. Ceftriaxone 2.0 g of a once-daily intravenous infusion, and 10 days later - klaforan
2.0 g 2 times a day by intravenous infusion or intramuscular injection, and 10 days, then -
amoxicillin 0.5 g three times daily per os (0.375 g of amoxiclav three times daily
per os), 7 days.
 or
Two. Ceftriaxone 2.0 g of a once-daily intravenous infusion, and 10 days later - klaforan
2.0 g 2 times a day by intravenous infusion or intramuscular injection, and 10 days, then -
doxycycline 0.1 g 2 times a day by intravenous drip, and 10 days.

Chronic (Stage subcompensation)

(Schema therapy - individual choice of doctor)
A. Ceftriaxone 2.0 g of a once-daily intravenous infusion, and 10 days later - klaforan
2.0 g 2 times a day by intravenous infusion or intramuscular injection, and 10 days, then -
amoxicillin 0.5 g three times daily per os (0.375 g of amoxiclav three times daily
per os), 10 days.
 or
Two. Ceftriaxone 2.0 g of a once-daily intravenous infusion, and 10 days later - klaforan
2.0 g 2 times a day by intravenous infusion or intramuscular injection, and 10 days, then -
doxycycline 0.2 g 2 times a day by intravenous drip, and 10 days.

9Hronicheskoe for (stage decompensation)

(Schema therapy - individual choice of doctor)
A. Ceftriaxone 2.0 g of a once-daily intravenous infusion, and 10 days later - klaforan
2.0 g 2 times a day by intravenous infusion or intramuscular injection, and 10 days, then -
amoxicillin 0.5 g three times daily per os (0.375 g of amoxiclav three times daily
per os), 10 days.
 or
Two. Ceftriaxone 2.0 g of a once-daily intravenous infusion, and 10 days later - klaforan
2.0 g 2 times a day by intravenous infusion or intramuscular injection, and 10 days, then -
doxycycline 0.2 g 2 times a day by intravenous drip, and 10 days.

Scheme of pathogenetic and symptomatic therapy

Universal scheme of pathogenetic and symptomatic therapy
patients with SDS

(Drugs, marked with #, appoint, and the testimony of an individual selection, dosing regimen of drugs - depending on the severity of illness)

- Lineks 1-2 capsules three times daily per os, 30 days;
# 0.9% sodium chloride, 200 ml of intravenous-drip of 5% glucose solution
200-400 ml of intravenous-drip reopolyglukine 200-400 ml of intravenous-ka-
pelno;

# Immunomodulators (including data immunogram).

When neurological manifestations...

# Venotonicheskie tools
- 2.4% -10.0 aminophylline IV-drip, 10 days
or
- Cavinton (vinpocetine) 4-mL intravenous infusion, 10 days
# Neuroprotective drugs
- 10 ml Cerebrolysin intravenous-infusion, 10 days
or
- Actovegin 5-20 ml per day by intravenous drip, and 10 days later - on 0.2 g of 3
times a day per os, 30 days
or
- Cytoflavin 10 ml intravenous drip, in 100-200 ml of 5-10% solution of glucoside
goats, or 0.9% sodium chloride solution, 1 time per day, 10 days later - on 2
tablets 2 times daily per os, 25-30 days
or
- Nootropil 5 ml intravenous drip, and 10 days
or
- Lutset 10 ml intravenous bolus, and 10 days

# Metabolic means

- Mildronat 10% -5.0 (10.0) IV-bolus, 10 days
or
- Panangin 10-20 ml intravenous bolus, and 10 days, then - 1 tablet 3 times a
per day per os, 30 days

# Vitamin
- Milgamma 2 ml daily intramuscular injections of 10
or
1011
- Berokka plus 1 tablet daily per os, 30 days
or
- Benfolipen (combined multivitamin complex) 1 tablet 1.3
times daily after meals per os, 30 days

# Tranquilizers
- Nozepam of 0.01 g per os the night
or
- Grandaksin of 0.05 g 2 times a day per os
or
- Alprazolam 0,025 g per night per os, with a gradual increase in dose
0.025 g in 3-5 days
or
- Phenazepam of 0.005-0.01 g per night per os, 7-10 days
or
- Glycine, 0.1 g 4-6 times a day sublingually, long-term (period-rekonva
lestsentsii)
or
- Adaptol (mebikar) to 0.5 g 2-3 times a day per os, a few days to 2-3
months (the period of convalescence)

# Sedatives
- New-passive 1 tablet or 1 tsp. solution 3 times a day per os, 30 days
or
- Tincture of motherwort (peony, Valerian) or Corvalol (valokordin, valoser-
din)

otvornye tools
- Donormil to 0,015 g per night per os
or
- Radedorm to 0,005 g per night per os
or
- Ivadal of 0.010 g per os the night
or
- Imovan of 0.0075 g per night per os
or
- Sanval to 0,005 g per night per os

# antidepressants
- Amitriptyline to 0,025 g per night per os, with a gradual increase in dose
0.025 g, 30-40 days
or
- Luvox of 0.05-0.1 g per night per os, up to 3 months
or
- Agomelatine 0,025 g per night per os, up to 3 months
When arthrologic manifestations

# Non-steroidal anti-inflammatory drugs
- Diclofenac 3 ml intramuscular injections of 6 or 0.025-0.05 g 3 times
per day per os, up to 7 days
or
- Movalis 1.5 mL intramuscularly or 0.015 g of 1 time per day per os, up to 7 days
or 12
- Ksefokam of 0,008 g 1-2 times daily per os
or
- Celebrex to 0.2 g 2 times a day per os, up to 7 days
or
- Artrozan (meloxicam) to 0,015 g 1 a day per os

# Antispasmodics
- Midokalm of 0.05 g 2-3 times a day per os, with a gradual increase razo-
curve to the dose of 0.15 g (0.1 g 1-2 times a day intramuscularly or intravenously
slowly)
or
- Sirdalud 0,002 g 3 times a day

# With the express pain
- Diprospan 1 ml in 2-4 ml of 0.5% solution of novocaine or lidocaine 2%
an intramuscular injection once a week, 3-5 injections
or
- Combilipen (combined multivitamin complex in conjunction with the Do-
dokainom) 2 ml intramuscularly daily for 5-7 days, then - 2
ml 2-3 times a week for 2 weeks

# Massage, therapeutic exercise, physical therapy (in the period of convalescence)

When cardiac manifestations...

# Metabolic means
- 10% mildronat -5,0-10,0 intravenous bolus, and 10 days (myocarditis, myocardial-
odistrofiya, ECG signs of repolarization, disturbances of rate)
- Panangin 10-20 ml intravenous bolus, and 10 days, then - 1 tablet 3 times a
per day per os, 30 days (arrhythmias and conduction)

# Sedatives
- New-passive 1 tablet or 1 tsp. solution 3 times a day per os, 30 days
(Syndrome of vegetative dystonia)
or
- Tincture of motherwort (peony, Valerian) or Corvalol (valokordin, valoser-
din)

# Antihypertensives
- Atenolol to 0.05-0.1 g per day, 20-30 days (arterial hypertension syndrome-
sion, cardiac arrhythmias, the syndrome of vegetative dystonia, stenokardicheskie
syndrome)



Comments? Questions? Thoughts?

My first thought on these guidelines are that the first thing I notice is that they are broken down into certain stages and conditional stages of Lyme disease/Borreliosis that are not defined here - perhaps they are defined in another document I have yet to locate, but just at first glance, medical professionals in Russia seem to break the stages down into finer grades of distinction with treatments to match.

My second thought is it seems their approach is to vary the kind of antibiotic used, and use the most bactericidal antibiotic first, followed by progressively less bactericidal and more bacteriostatic antibiotics. I am wondering if this is done for any specific reason.

My third thought is that the IDSA would probably not like part of these guidelines because they recommend using vitamins, massage therapy, and a little alternative medicine. That tincture of motherwort would probably be troubling to them. (Personally, I found valerian root to be a useful sleep aid, but it smells like dirty socks so I don't use it.)

My fourth thought is that this is pretty thorough in terms of intensive treatment for patients with cardiac and neurological manifestations of disseminated and late stage Lyme disease/Borreliosis, and I like that it offers ideas for supportive treatment for not only pain, anxiety, and depression - but for irregular heart rhythms.

There are some things that didn't translate well and I'm wondering what they are. "8Podostroe" for one thing."9Hronicheskoe" for another... I don't know what that is, either. Readers are invited to guess.

One thing I have learned while looking at various Russian and Balkans regional web sites on Lyme disease: They take it seriously.

You are considered an early mild case only within the first few days of a bite. After that, there is concern the disease has moved to the disseminated phase and it is treated more intensively. They also believe in relapses, and will give additional antibiotics if the initial course fails. In a number of places, you are expected to visit an infectious disease doctor as an outpatient 1, 3, 6, and 12 months after treatment in order to get follow up testing, report any relapsing, ongoing, or new symptoms, and give doctors more data for them to collect to understand how Lyme disease affects people.

There's more I've learned, but I'll share it later. Right now I just wanted to put these out here for you to see what other countries are doing to treat Lyme disease.


Read More

Wednesday, January 4, 2012

0 Camp Other Blog: 2011 In Review

A little over a year ago, I set out to write about the Chicago Tribune's article, "Chronic Lyme: A Dubious Diagnosis". My analysis of that article formed the basis for this blog, and from there, I hit the ground running.

I didn't know how long I'd write here or how often. Or know whether or not wrestling with chronic illness would interfere with writing. Sometimes it has. Sometimes it hasn't.

One year later, and I'm still here. Perhaps a bit battered around the edges. Tired. Exhausted. Overwhelmed, even. Disappointed with the lack of more treatment research for myself and my fellow sufferers. But also more knowledgeable, less naive, and more curious than when I began. Open to more new ideas. Questioning.

I'm somewhat amused this blog gets as much traffic as it has during the past year and it has only increased as time went on. I never expected it to be The Popular Blog Online, given the somewhat esoteric subject matter at times - but perhaps these stats mean something?

January 2011: 1,379 page views
March 2011: 2,539 page views
June 2011: 3,957 page views
November 2011: 5,579 page views

And for the most part, this trend in traffic increase continues. It only tends to dip down when I don't write something for a long time.

There were over 40,000 visits to this site during 2011 from over 114 countries - with the top ten countries' visitors coming from the United States, Canada, Russia, Slovenia, Germany, United Kingdom, Ukraine, Netherlands, India, and France. And there are over 104 more, from Australia to Algeria. This blog has had an ongoing international audience since it began.

Where Camp Other Is Read: Around The World
On average, about half my visitors are people who return to read something new on my blog. Some are repeat checkers who must hit refresh for the homepage daily or something. Sometimes they are deliberately looking in my archives. (I don't know why - hey, you're reading - perhaps you can tell me why?) The other half of my visitors are people using google and other search engines for specific research, possibly for university papers or their own personal education. Their keyword searches are often incredibly specific; with a keyword choice like "Borrelia burgdorferi + bacteriophage" they often end up here.

I didn't know who would be interested in reading along. Or how many people would want to scour Lyme disease related research and publications with me. But it seems like quite a number of you are interested because you keep coming back.

To you, I say thank you. Even if you have never commented on this blog, if you have been getting something positive out of being here and learned something new, that makes it worth it to write. It inspires me to keep going even when the going is tough.

(And I will say that my underwhelming publishing schedule in December was not only the result of holiday insanity/busyness my family participates in - it was also the result of life and my health being tough.)

(And it still is. I can't guarantee any sort of content/timeline/publishing schedule right now.)

But I made it this far, so I'd like to share some of the highlights of this blog from 2011:

In January, the blog looked at polymicrobial infections - also known as Lyme disease coinfections. How common are coinfections? What is the most recent body of literature on coinfections? What kind and severity of symptoms do patients with coinfections have? We took a preliminary look at these questions.

In February, we examined the different uses of the term, "chronic Lyme disease", and I wrote about how the IDSA Lyme disease guidelines group would label my condition - versus how patient advocates would label my condition. This link has been very popular during the past year up to now: http://campother.blogspot.com/2011/02/is-chronic-lyme-real.html

In addition to wrangling with disease definitions, in February there was much buzz about an old patent that I decided to comment on (including for its use of the above terminology), the VlsE sequence in Borrelia burgdorferi (as discussed at the 2010 Institute of Medicine workshop on tickborne diseases), and the interesting package insert from the Athena Multi-Lyte Borrelia VlsE Test, which states, "Lyme disease occurs in stages, often with intervening latent periods and with different clinical manifestations," and "Also, early antibiotic therapy after EM may diminish or abrogate good antibody response. Some patients may never generate detectable antibody levels." Yes, Virginia, there can be seronegative Lyme disease.

In March, the blog reviewed the 1993 U.S. Congressional Senate Testimony On Lyme Disease in two parts, including questions and commentary on various sections. We also discovered the value of anecdotal evidence, and offered links to online video tutorials on the immune system for beginners.

In April, we introduced readers to a blog about spirochete microbiology, Spirochetes Unwound. We also reviewed an outline of the book, "Borrelia: Molecular Biology, Host Interaction and Pathogenesis", and listed many definitions and terms used in Borrelia microbiology. Two other popular articles or series were published during this month - a two-part series on phage therapy: "One Way To Treat Borrelia Naturally?" and "Phage Therapy and Borrelia burgdorferi". We also shared a two-part series on neuroborreliosis based on the Institute of Medicine's 2010 tickborne disease workshop notes, and shared the news that a serious allergy to red meat can develop in some people who have had a tick bite.

In May, Camp Other blog contributed a series of posts at The Daily Kos in observance of Lyme Disease Awareness Month, and reposts of these posts can be found in May 2011 archives. Of the lot, I think "Lyme Disease Rant: The Wall Of Polarization" is particularly important for those engaged in discussing both sides of the Lyme disease controversy online. We also looked at someone's thesis, "Environmental Stress in Borrelia burgdorferi", and some initial late stage Lyme disease study outcomes from the 2000 Lyme disease guidelines.

In June, the blog took a preliminary look at the 2006 Lyme disease guidelines, examined the paper - "Borrelia burgdorferi RST1 (OspC Type A) Genotype Is Associated with Greater Inflammation and More Severe Lyme Disease" - on the growing evidence of differential pathogenicity among Borrelia burgdorferi genotypes in the United States, shared Dr. Elizabeth Maloney's critique of the IDSA Lyme disease guidelines, and wrote a critique of a (which has yet to be confirmed as official) letter from the CDC to a Lyme disease patient who had written looking for more information on Lyme disease.

In July, we referred to our favorite spirochete blog, Spirochetes Unwound, to learn more about Barthold's study on how Lyme disease affects the immune system in lymph nodes, asking the question: "Does Borrelia burgdorferi cause an inadequate antibody response by altering B cell activation in the lymph node?" We shared an overview of Lyme disease in vitro studies showing intracellular behavior, examined how Google can aggregate data sets for Lyme disease using Google Trends, and broadcast the news that a teen from North Carolina developed a serious allergic reaction to meat after a tick bite.

In August, the blog discussed the publication of a paper on the link of antibodies to long term symptoms related to Lyme disease infection, introduced readers to a new patient blog: Lyme Jello, and examined whether or not there is a connection between different genetic haplotypes (HLA-DR#) and Lyme disease in two related posts. I think, though, that the most profoundly compelling post of August (and related to the previous two) was this one: "Immune + Infection = HLA-DR alleles determine responsiveness to Borrelia burgdoferi."

In September, the blog looked at the development of new Lyme disease detection tests for patients, published two articles on the recognition that Borrelia miyamotoi can cause infection in patients in the United States, speculation about Borrelial blebbing and camouflage, and speculation on the role of cholesterol in Borrelia burgdorferi.

In October, the blog speculated what kind of new Lyme disease research may be useful, we learned that a Chacolithic iceman from 5,000 years ago had Lyme disease, we looked at a new molecular test which may be able to detect early Lyme disease, and reviewed the Stony Brook Young Investigators Series On Lyme Disease.

In November, the official final report of the Institute of Medicine workshop was published on Pubmed: "Critical Needs and Gaps in Understanding: Prevention, Amelioration, and Resolution of Lyme and Other Tick-Borne Diseases: The Short-Term and Long-Term Outcomes," a Tularemia outbreak hit Australia, and there were two notable articles published on long-term outcomes of antibiotic use as well as using cathelicidins as an alternative to antibiotic use. Perhaps one of my favorite links for November was about a series of articles by Slate on the use (and drawbacks) of the murine (mouse) model for researching human models of disease.

In December, the blog shared an outline and separate discussion on presentation summaries from the 2011 Lyme and Tick-Borne Diseases National Conference held in October 2011. The news of a new strain of Ehrlichiosis that is causing disease in Sweden was reported, and we took a look at concerns over a Canadian freedom of information request and response over patient advocacy and supportive treatment of Lyme disease at a new Vancouver Complex Chronic Disease Clinic.

So, those are the highlights of the past year in review.

What will 2012's blog posts have in store for you? Stay tuned...


Read More

The Camp Other Song Of The Month


Why is this posted? Just for fun!

Get this widget

Lyme Disease

Borrelia

Bacteria

Microbiology